Abstract
Survivin inhibits apoptosis and promotes mitosis. We determined whether nuclear or cytoplasmic localisation of survivin predicts survival of 48 patients with resected non-small-cell lung cancer (NSCLC). Patients with nuclear staining of survivin had significantly worse survival (relative risk: 3.9, P=0.02). Therefore, survivin may be a biomarker for NSCLC.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Aged
-
Apoptosis
-
Biomarkers, Tumor / analysis*
-
Carcinoma, Non-Small-Cell Lung / pathology*
-
Cell Nucleus / chemistry*
-
Cysteine Proteinase Inhibitors / analysis*
-
Cytoplasm / chemistry
-
Female
-
Humans
-
Immunohistochemistry
-
Inhibitor of Apoptosis Proteins
-
Lung Neoplasms / pathology*
-
Male
-
Microtubule-Associated Proteins / analysis*
-
Middle Aged
-
Neoplasm Proteins
-
Prognosis
-
Retrospective Studies
-
Survival Analysis
-
Survivin
Substances
-
BIRC5 protein, human
-
Biomarkers, Tumor
-
Cysteine Proteinase Inhibitors
-
Inhibitor of Apoptosis Proteins
-
Microtubule-Associated Proteins
-
Neoplasm Proteins
-
Survivin